Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Description:This image depicts the packaging that will be implemented, which will contain the MedImmune, Influenza Vaccine Live, Intranasal FluMist® Quadrivalent, for 2014-2015.
FluMist® is a Live Attenuated Influenza Vaccine (LAIV), indicated for active immunization for the prevention of influenza disease caused by influenza-A subtype viruses, and the type-B virus contained in the vaccine, or four influenza virus strains, hence the term, quadrivalent. FluMist® is approved for use in persons 2 through 49 years of age. FluMist® is administered as a 0.2ml intranasal spray, that is introduced into the nose, 0.1ml into each nostril.
High Resolution: Click here for hi-resolution image (15.65 MB)
Content Providers(s):CDC/ Heather Richmond, MedImmune
Creation Date:2014
Photo Credit:Kaye evens-lutterodt/PR Neswire
Links:CDC - National Center for Immunization and Respiratory Diseases (NCIRD); Influenza (Flu)
CDC - Morbidity and Mortality Weekly Report (MMWR); Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 Influenza Season
CDC Organization
Skip Navigation Links.

Skip Navigation Links.
Copyright Restrictions:None - This image is in the public domain and thus free of any copyright restrictions. As a matter of courtesy we request that the content provider be credited and notified in any public or private usage of this image.